DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
1SXP logo

SCHOTT Pharma AG & Co. KGaA Stock Price

XTRA:1SXP Community·€3.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

1SXP Share Price Performance

€23.05
1.80 (8.47%)
​
€20.43
Fair Value
€23.05
1.80 (8.47%)
12.8% overvalued intrinsic discount
€20.43
Fair Value
Price €23.05
AnalystConsensusTarget €20.43
AnalystLowTarget €14.96
AnalystHighTarget €27.00
Wed, 15 Jul 26
Fair Value€20.43
Share Pricen/a

1SXP Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €20.43 12.8% overvalued intrinsic discount

Advanced Drug Delivery And Capacity Investments Will Shape Future Success

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €14.96 54.1% overvalued intrinsic discount

Intensifying Climate Mandates And Protectionism Will Erode Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €27 14.6% undervalued intrinsic discount

Aging Population And Biologics Growth Will Fuel Advanced Packaging

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
1SXP logo
SCHOTT Pharma KGaA
54.1% overvalued intrinsic discount

Intensifying Climate Mandates And Protectionism Will Erode Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
1SXP logo
SCHOTT Pharma KGaA
14.6% undervalued intrinsic discount

Aging Population And Biologics Growth Will Fuel Advanced Packaging

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 13 Aug
Read Narrative
1SXP logo
SCHOTT Pharma KGaA
12.8% overvalued intrinsic discount

Advanced Drug Delivery And Capacity Investments Will Shape Future Success

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 15 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
1SXP logo

1SXP: Higher Future P/E And Rich Margins Will Limit Share Return Potential

Fair Value: €14.96 54.1% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
1SXP logo

1SXP: Expanded U.S. Vial Capacity Will Support Future Upside For Undervalued Shares

Fair Value: €27 14.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
1SXP logo

1SXP: Lebanon Expansion And Confirmed 2026 Guidance Will Support Balanced Outlook

Fair Value: €20.43 12.8% overvalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

0 Risks
2 Rewards
View Full Analysis

SCHOTT Pharma AG & Co. KGaA Key Details

€1.0b

Revenue

€699.9m

Cost of Revenue

€316.9m

Gross Profit

€180.7m

Other Expenses

€136.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Dec 10, 2026
0.90
31.17%
13.40%
23.2%
View Full Analysis

About 1SXP

Founded
1884
Employees
5002
CEO
Christian Mias
WebsiteView website
www.schott-pharma.com

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Recent 1SXP News & Updates

User avatar
Narrative Update • Sep 03

1SXP: Higher Future P/E And Rich Margins Will Limit Share Return Potential

Analysts have raised their price target for SCHOTT Pharma KGaA from €13.00 to about €14.96, citing updated assumptions for revenue growth, profit margins, and future P/E that support a higher estimated fair value. What’s in the News for SCHOTT Pharma KGaA There are currently no recent news stories or key developments provided for SCHOTT Pharma KGaA based on the available sources.
Analysis Article • Aug 15

SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Just Reported And Analysts Have Been Lifting Their Price Targets

Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) released its third-quarter result to the...

Recent updates

No updates

SCHOTT Pharma AG & Co. KGaA Competitors

DMP logo

Dermapharm Holding

Symbol: XTRA:DMP
Market cap: €1.9b
28L logo

PEPTONIC medical

Symbol: DB:28L
Market cap: €1.7b
7ZT logo

Hamlet BioPharma

Symbol: DB:7ZT
Market cap: €1.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide